Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 7/20 | 1.00 |
| ▸ | CA1 | P00915 | 1/20 | 0.76 |
| ▸ | CA2 | P00918 | 1/20 | 0.76 |
| ▸ | CA4 | P22748 | 1/20 | 0.76 |
| ▸ | CA9 | Q16790 | 1/20 | 0.76 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.73 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.73 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.73 |
| ▸ | NT5E | P21589 | 3/20 | 0.69 |
| ▸ | P2RY1 | P47900 | 6/20 | 0.67 |
| ▸ | P2RY11 | Q96G91 | 4/20 | 0.67 |
| ▸ | CD99 | P14209 | 1/20 | 0.63 |
| ▸ | PDE2A | O00408 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4451649 | 1.00 | ADORA3 (1.00) | ADORA3CA1CA2CA4CA9 | |
| SCHEMBL16366300 | 0.91 | ADORA3 (0.83) | ADORA3ADORA2AADORA1NT5ECD99 | |
| SCHEMBL5355275 | 0.89 | ADORA3 (1.00) | ADORA3CA1CA2CA4CA9 | |
| SCHEMBL5355268 | 0.89 | ADORA3 (1.00) | ADORA3CA1CA2CA4CA9 | |
| SCHEMBL18526554 | 0.89 | ADORA3 (0.80) | ADORA3CA1CA2CA4CA9 | |
| SCHEMBL4454099 | 0.89 | ADORA3 (0.80) | ADORA3CA1CA2CA4CA9 | |
| SCHEMBL1938203 | 0.89 | ADORA3 (0.80) | ADORA3CA1CA2CA4CA9 | |
| SCHEMBL12443734 | 0.89 | ADORA3 (0.80) | ADORA3CA1CA2CA4CA9 | |
| SCHEMBL8622533 | 0.88 | ADORA3 (0.78) | ADORA3CA1CA2CA4CA9 | |
| SCHEMBL29936666 | 0.88 | ADORA3 (0.78) | ADORA3CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844063-A4 | PURINE NUCLEOSIDE ANALOGS | UTI LIMITED PARTNERSHIP (CA) | 2009-06-17 | — | — | EP | claimed |
| US-20080070860-A1 | Purine nucleoside analogs that are selective ligands of the purine salvage pathway enzyme adenosine phosphorylase (AP) found in bacteria and protozoa; 2-chloro-5'-deoxyadenosine; 2-chloro-6-methylpurine-5'-deoxyriboside | UTI LIMITED PARTNERSHIP (CA) | 2008-03-20 | — | — | US | claimed |
| EP-1844063-A1 | PURINE NUCLEOSIDE ANALOGS | Uti Limited Partnership (CA) | 2007-10-17 | — | — | EP | claimed |
| US-7189706-B2 | C2,5′-disubstituted and N6,C2,5′-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | UNIVERSITEIT LEIDEN (NL) | 2007-03-13 | — | — | US | claimed |
| WO-2006081665-A1 | PURINE NUCLEOSIDE ANALOGS | UTI LIMITED PARTNERSHIP (CA) | 2006-08-10 | — | — | WO | claimed |
| US-7084127-B2 | C2,5′-disubstituted and N6, C2,5′-trisubstituted adenosine derivatives and their different uses | UNIVERSITEIT LEIDEN (NL) | 2006-08-01 | — | — | US | claimed |
| US-20040132686-A1 | C2,5'- disubstituted and N6, c2,5'- trisubstituted adenosine derivatives and their different uses | UNIVERSITEIT LEIDEN (NL) | 2004-07-08 | — | — | US | claimed |
| US-20040127452-A1 | C2,5'-disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | UNIVERSITEIT LEIDEN (NL) | 2004-07-01 | — | — | US | claimed |
| EP-1844063-A4 | PURINE NUCLEOSIDE ANALOGS | UTI LIMITED PARTNERSHIP (CA) | 2009-06-17 | — | — | EP | disclosed |
| US-20080070860-A1 | Purine nucleoside analogs that are selective ligands of the purine salvage pathway enzyme adenosine phosphorylase (AP) found in bacteria and protozoa; 2-chloro-5'-deoxyadenosine; 2-chloro-6-methylpurine-5'-deoxyriboside | UTI LIMITED PARTNERSHIP (CA) | 2008-03-20 | — | — | US | disclosed |
| EP-1844063-A1 | PURINE NUCLEOSIDE ANALOGS | Uti Limited Partnership (CA) | 2007-10-17 | — | — | EP | disclosed |
| US-7189706-B2 | C2,5′-disubstituted and N6,C2,5′-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | UNIVERSITEIT LEIDEN (NL) | 2007-03-13 | — | — | US | disclosed |
| WO-2006081665-A1 | PURINE NUCLEOSIDE ANALOGS | UTI LIMITED PARTNERSHIP (CA) | 2006-08-10 | — | — | WO | disclosed |
| US-7084127-B2 | C2,5′-disubstituted and N6, C2,5′-trisubstituted adenosine derivatives and their different uses | UNIVERSITEIT LEIDEN (NL) | 2006-08-01 | — | — | US | disclosed |
| US-20040132686-A1 | C2,5'- disubstituted and N6, c2,5'- trisubstituted adenosine derivatives and their different uses | UNIVERSITEIT LEIDEN (NL) | 2004-07-08 | — | — | US | disclosed |
| US-20040127452-A1 | C2,5'-disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | UNIVERSITEIT LEIDEN (NL) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070860-A1 | Purine nucleoside analogs that are selective ligands of the purine salvage pathway enzyme adenosine phosphorylase (AP) found in bacteria and protozoa; 2-chloro-5'-deoxyadenosine; 2-chloro-6-methylpurine-5'-deoxyriboside | PNP, MTAP, TYMP | ADORA3 30/4885CA1 3582/4885CA2 1351/4885 |
| US-20040127452-A1 | C2,5'-disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885CA1 4117/4885CA2 1681/4885 |
| US-20040132686-A1 | C2,5'- disubstituted and N6, c2,5'- trisubstituted adenosine derivatives and their different uses | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885CA1 4122/4885CA2 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.